ACE-031

What is ACE-031?

ACE-031 (ramatercept) is an engineered biologic — specifically, the extracellular ligand-binding domain of the human activin receptor type IIB (ActRIIB) fused to the Fc region of human IgG1. It functions as a soluble decoy receptor, or 'ligand trap,' that binds and sequesters myostatin (GDF-8), activin A, GDF-11, and BMP9/10 in circulation, preventing them from engaging membrane-bound ActRIIB on muscle and vascular cells. By sequestering the natural inhibitor myostatin and related TGF-β superfamily ligands, ACE-031 releases the brake on skeletal muscle growth. Developed by Acceleron Pharma in Cambridge, Massachusetts (later partnered with Shire for the DMD program, and ultimately acquired by Merck in November 2021), ACE-031 is no longer in active clinical development. Its Phase 1 study in healthy postmenopausal women showed measurable gains in lean body mass and thigh muscle volume after a single subcutaneous dose, and a Phase 2 dose-escalation study in ambulatory boys with Duchenne muscular dystrophy produced encouraging pharmacodynamic signals — but the DMD program was halted in April 2011 after nose-bleed, gum-bleed, and telangiectasia adverse events emerged, attributed to off-target blockade of BMP9/10 vascular signaling. Acceleron deprioritized the molecule; the receptor-trap approach lived on in successor programs (bimagrumab at Novartis, apitegromab at Scholar Rock with a different selectivity).

What ACE-031 Is Investigated For

ACE-031 is best understood as a historical drug program with archived clinical data rather than an active therapeutic. The strongest human evidence is the 2013 Attie Phase 1 single-ascending-dose study in 48 healthy postmenopausal women, which reported statistically significant gains in total body lean mass (~3.3% by DXA) and thigh muscle volume (~5.1% by MRI) at day 29 following the 3 mg/kg dose — a striking result for a single subcutaneous injection. The 2017 Campbell Muscle & Nerve paper reported the halted Phase 2 dose-escalation study in ambulatory boys with Duchenne muscular dystrophy, which showed lean-mass and functional trends favoring ACE-031 but was discontinued at Acceleron's decision in April 2011 after epistaxis, gum bleeding, and telangiectasia were observed at the higher dose cohort. These vascular findings are attributed to off-target blockade of BMP9 and BMP10 signaling through ActRIIB on endothelial cells — a mechanism intrinsic to receptor-level ligand trapping and distinct from selective myostatin-only antibodies. Acceleron subsequently deprioritized ACE-031 (and its related muscle programs) in favor of its hematology and pulmonary hypertension assets, was acquired by Merck in 2021, and the molecule never resumed clinical development. Successor approaches in the ActRII class — Novartis/Lilly's bimagrumab (ActRIIA/B dual antagonist antibody) and Scholar Rock's apitegromab (latent-myostatin-selective antibody) — have pursued the same muscle biology with different selectivity profiles in an effort to retain efficacy while avoiding the ACE-031 vascular signal. Fitness-community interest in ACE-031 persists because research-chemical vendors continue to sell products labeled 'ACE-031,' but these are not the Acceleron biologic, no sanctioned human availability exists, and WADA explicitly prohibits decoy activin receptors under its S4.3 class.

History & Discovery

ACE-031 emerged from Acceleron Pharma, the Cambridge, Massachusetts biotech founded in 2003 by John Knopf, Jasbir Seehra, Tom Maniatis, and colleagues to commercialize the TGF-β-superfamily receptor biology pioneered in Jeff Wrana's and Joan Massagué's academic work. Acceleron's founding insight was that the activin-receptor family — ActRIIA and ActRIIB — sits at the top of several important disease-relevant signaling branches (muscle, hematopoiesis, vascular biology, bone), and that soluble extracellular-domain Fc fusions could serve as disease-modifying 'ligand traps' with desirable pharmacokinetics. ACE-031 was the muscle-focused asset, based on the ActRIIB extracellular domain; sotatercept (ACE-011) and luspatercept (ACE-536) were related ActRIIA-based traps targeting erythropoiesis and bone biology. The ACE-031 Phase 1 single-ascending-dose study in healthy postmenopausal women (NCT00707512), published by Attie and colleagues in Muscle & Nerve in 2013, established the program's muscle-mass pharmacodynamics and tolerability at single-dose exposures, producing the headline ~3.3% lean-mass and ~5.1% thigh-muscle-volume increases at day 29 in the 3 mg/kg cohort. Based on that signal, Acceleron partnered with Shire for Duchenne muscular dystrophy development and launched a Phase 2 multiple-ascending-dose study in ambulatory DMD boys (NCT01099761) in 2010. The trial enrolled across centers in the US and Canada and used weight-based subcutaneous dosing every two to four weeks. In April 2011, Acceleron and Shire announced that the Phase 2 study and its open-label extension were being halted because the second dose cohort had developed epistaxis, gum bleeding, and telangiectasias — findings attributed to off-target blockade of BMP9 and BMP10 vascular signaling through ActRIIB. The events themselves were described as not medically serious and resolved on discontinuation, but the sponsors judged the risk/benefit inadequate for chronic pediatric dosing. The halted study was written up by Campbell and colleagues in Muscle & Nerve in 2017. Acceleron deprioritized the muscle program. The company's center of gravity shifted to sotatercept (for pulmonary arterial hypertension — eventually approved in 2024 as Winrevair under Merck's ownership) and luspatercept (for anemia in myelodysplastic syndromes and β-thalassemia — approved in 2019 as Reblozyl under the Celgene/BMS partnership). Merck acquired Acceleron for approximately $11.5 billion in November 2021, primarily for sotatercept. ACE-031 has not returned to clinical development. The receptor-trap thesis for muscle did not die with ACE-031. Novartis's bimagrumab (BYM338), a monoclonal antibody against ActRIIA/B, moved through sporadic inclusion body myositis, sarcopenic obesity, and related indications — with Versanis (acquired by Lilly in 2023 for $1.9 billion) driving subsequent obesity combination work. Scholar Rock's apitegromab (SRK-015), a highly selective antibody against the pro- and latent forms of myostatin — engineered specifically to avoid the broader TGF-β pathway blockade that caused ACE-031's vascular signal — completed the Phase 3 SAPPHIRE trial in non-ambulatory SMA with a 2025 readout. The lesson the field took from ACE-031 is that receptor-level ligand trapping produces broader efficacy but also broader off-target liability, and that selective upstream myostatin targeting is the safer long-term path.

How It Works

Your muscle cells have a receptor called ActRIIB that receives 'stop growing' signals — myostatin is the most famous of those signals, but activin A and a few others use the same receptor. ACE-031 is an engineered decoy: it's the outer ligand-binding part of that receptor, stitched onto an antibody tail so it floats in the bloodstream. It binds and soaks up those 'stop' signals before they reach your muscle, letting muscle grow more than it otherwise would. The problem that halted its development: BMP9 and BMP10, two vascular-signaling proteins, also use that same receptor — and soaking them up produced nosebleeds and visible small-vessel changes in the skin, so the trial was stopped.

ACE-031 is a recombinant homodimeric fusion protein composed of the extracellular ligand-binding domain of human activin receptor type IIB (ActRIIB) genetically fused to the hinge-CH2-CH3 region of human IgG1 Fc. The Fc confers extended plasma half-life via FcRn recycling (supporting dosing intervals measured in weeks) and enables homodimer formation, which is important for high-avidity ligand binding. The extracellular ActRIIB domain binds with high affinity a cluster of TGF-β superfamily ligands that use ActRII receptors for signaling: myostatin (GDF-8), activin A and activin B, GDF-11 (a close myostatin paralog), and BMP9 and BMP10. By sequestering these ligands in the circulation, ACE-031 prevents them from engaging membrane-bound ActRIIB (and to a lesser extent ActRIIA) on target cells. In muscle, this blocks recruitment of ALK4/ALK5 type I receptors and downstream Smad2/3-mediated transcription that normally drives muscle-atrophy gene expression (including the E3 ubiquitin ligases MuRF1 and atrogin-1) and restrains the Akt/mTOR anabolic axis — producing a net pro-hypertrophic, anti-atrophic shift. The off-target consequence that defined ACE-031's clinical fate is BMP9/10 sequestration. BMP9 and BMP10 (encoded by GDF2 and BMP10) are circulating TGF-β superfamily ligands critical to vascular endothelial quiescence, quality of capillary networks, and hemostatic function. Loss-of-function in these pathways — whether from genetic disease (hereditary hemorrhagic telangiectasia, where ENG, ACVRL1, or GDF2 mutations produce telangiectasias, epistaxis, and arteriovenous malformations) or pharmacologic blockade — produces a recognizable vascular phenotype. The telangiectasia and epistaxis reported in the Phase 2 DMD dose-escalation are consistent with that biology. This informed the entire next generation of myostatin-pathway drug design, which has pursued increasingly selective targeting — antibodies against myostatin alone, or against latent pro-myostatin before tolloid activation — specifically to avoid the BMP9/10 off-target seen with receptor-level ligand traps.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about ACE-031:

• 01Whether lower-dose or modified-regimen ACE-031 could retain lean-mass benefits while avoiding the epistaxis/telangiectasia signal — the dose-response for the muscle effect versus the vascular effect was never fully characterized before the program was halted.
• 02Long-term (multi-year) safety of chronic ActRIIB-Fc ligand trapping in humans, across any population — the clinical exposure that exists is measured in weeks to months.
• 03Durability and functional translation — whether the reported ~3–5% lean-mass and thigh-muscle-volume gains translate to sustained strength, walking-distance, or patient-meaningful benefit over years of dosing in muscular dystrophy or sarcopenia.
• 04Cardiac safety — myostatin-pathway inhibition produces cardiac hypertrophy in preclinical models, and whether receptor-level trapping has clinically significant cardiac effects in humans was never rigorously characterized.
• 05Whether selective BMP9/10-sparing redesigns of the receptor trap (engineered to bind myostatin, activin, and GDF-11 while releasing BMP9/10) are feasible and would recapitulate the muscle efficacy without the vascular liability — a question the field has largely answered by switching to selective upstream antibodies instead.
• 06Identity and pharmacology of research-chemical 'ACE-031' — what is actually in vials sold under the ACE-031 or ramatercept name outside sanctioned pathways is not characterized, and is almost certainly not the Acceleron biologic.
• 07Comparative performance versus modern selective myostatin antibodies (apitegromab, trevogrumab) and dual ActRII antibodies (bimagrumab) in matched indications — a comparison that will never be run head-to-head because ACE-031 is discontinued.

Forms & Administration

Historically administered as subcutaneous injection of recombinant ACE-031 biologic. The Phase 1 healthy-volunteer study used a single subcutaneous dose at 0.02, 0.1, 0.3, 1, or 3 mg/kg. The Phase 2 DMD program used weight-based subcutaneous doses every two to four weeks (the specific dosing schedule reflected biologic half-life from Fc-mediated FcRn recycling). ACE-031 is not available for clinical, research, or compounded use; Acceleron's clinical program was halted in 2011 and Merck (which acquired Acceleron in 2021) has not resumed development. Material sold as 'ACE-031' in research-chemical channels is not the Acceleron biologic and should not be assumed to share its identity or pharmacology.

Common Questions

Who ACE-031 Is NOT For

Drug & Supplement Interactions

Formal drug-interaction data for ACE-031 are sparse because the development program was halted early. What follows is mechanism-based and theoretical. Concurrent use with other anabolic agents (androgens, SARMs, growth hormone, IGF-1, myostatin-pathway antibodies, or follistatin preparations) has not been studied and raises compound concerns: additive muscle effects may be desirable, but additive off-target vascular or endocrine effects have not been characterized. Co-administration with other agents that modulate TGF-β superfamily signaling — sotatercept, luspatercept, bimagrumab, apitegromab — would produce overlapping pathway blockade with unpredictable cumulative effects and is not advised outside a trial setting that explicitly designs for it. Antiplatelet and anticoagulant agents (aspirin, clopidogrel, warfarin, direct oral anticoagulants) warrant specific consideration given the bleeding-tendency signal (epistaxis, gum bleeding) observed at higher ACE-031 doses; combining a vascular-fragility-inducing agent with an antithrombotic would be expected to raise bleeding risk. Corticosteroids — which are standard-of-care in DMD — were co-administered in the halted Phase 2 trial under protocol management; formal interaction characterization was not completed. Patients on chronic medication of any kind, particularly cardiac, oncologic, or anticoagulant therapy, should treat a hypothetical ACE-031 exposure as an unstudied combination. Absence of documented drug interactions reflects absence of study, not absence of risk.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions